Johnson & Johnson's chief scientific officer Dr. Paul Stoffels said the drugmaker expects to have all the data needed to seek U.S. authorization of its COVID-19 vaccine by February or earlier. J&J are recruiting more than 1,000 people daily for the late-stage trial of its experimental treatment.
“By the end of the year or around the end of the year, we should have 60,000 people in the study,” said Stoffels. “And efficacy endpoint should be there in the first few weeks or months, January or February, of the new year."
The Phase III trial of the single-dose vaccine started in late September. The company paused the trial in October.
Read the Reuters report